CFO Mark Patrick discusses the enormous business opportunities available to Syngenta now that it's owned by a big Chinese company.
It's a broad restructuring of the German conglomerate, which plans to sell its sun-care and foot care businesses and exit its animal health division.
Analysts warn Bayer could face a "litigious headache" after the $289 million jury award in a product liability case over Monsanto's Roundup pesticide.
"Despite tough farm economics, we delivered a solid second quarter and are staying disciplined on near-term execution of the business," CEO Hugh Grant says.
The deal may help clear the way for European authorities to approve Bayer's acquisition of Monsanto early next year.
The German company is turning to an executive with U.S. corporate experience as it moves forward with its acquisition of Monsanto.
The deal continues the wave of consolidation in agribusiness, pairing Bayer's strength in crop chemicals with Monsanto's portfolio of seed products.
The deal would create the world's largest agricultural supplier but Bayer shareholders fear it will be detrimental to its pharmaceutical business
Lower prices, currency volatility, and regulatory delays are all playing a role in the weaker earnings forecast.
The SEC faults the company for booking millions of dollars in revenue from a rebate program while failing to recognize costs at the same time.
The largest overseas acquisition by a Chinese company will give ChemChina access to Syngenta’s advanced biotechnology for developing seeds.
Stay up-to-date with the best information on the web. The CFO roundup keeps you informed so you can get involved on every level of finance.
